| Name | Title | Contact Details |
|---|
Prologin Technologies Inc is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ring`s research team has uncovered the world`s largest collection of commensal anelloviruses and are harnessing these natural viruses to target a wide array of diseases with significant unmet need. The unique biology of anelloviruses provides a foundation for a revolutionary new platform and a new class of programmable medicines.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
Nacalai USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Virent Energy Systems is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.